Obsessive-Compulsive Disorder Clinical Trial
Official title:
Shanghai Mental Health Center in China
This study intends to explore the pathogenesis of obsessive-compulsive disorder(OCD) by using
biological technologies such as genetics and imaging, and to evaluate the efficacy of group
cognitive behavioural therapy in OCD among the Chinese people. We also prepare to explore the
synergistic effect of the pharmacological treatment combined with group cognitive behavioural
therapy in OCD, and to find the biological and psychological index which can predict curative
effect.
This research includes case control study and randomized controlled single-blind study. At
baseline, we compare the dimensions of clinical symptoms, genetics and imaging between OCD
patients and healthy controls. The OCD patients are randomly assigned into pharmacological
treatment, psychological treatment or pharmacological combined with psychological treatment
for a 12-week treatment. After a 12-week treatment, the OCD patients will be divided into
valid and invalid groups according to the results of our randomized controlled study by
researchers: to our valid group, patients will continue the current treatment, and to the
invalid psychological or pharmacological treatment group, patients will have a 12-week
combined treatment. From the baseline, we will have a 9-month follow up for both OCD patients
and healthy controls.
1. Case control study: At baseline, comparing the dimensions of clinical symptoms, genetics
and imaging between OCD patients and healthy controls who were chosen into our study.
2. Randomized controlled single-blind study: The OCD patients are randomly assigned into
pharmacological treatment, psychological treatment or pharmacological combined with
psychological treatment. Psychological treatment: every six or so patients can establish
a closed structured group. Each group will be treated for 12 sessions, for once a week,
120 minutes at a time. The 1-3 session will be psychological education on the topic of
OCD and cognitive behavioral therapy; The 4-6 and 8-10 session will do step by step
exposure and response prevention(ERP) training; the 7th an 11th session will invite
family members or other caregivers of OCD patients for a education about OCD cognitive
behavioral therapy to facilitate patients to complete ERP homework and give them some
social supports; the final session will be self treatment evaluation and long-term
treatment guidance. Pharmacological treatment: This study choose the SSRIs(Selective
Serotonin Reuptake Inhibitor:sertraline, fluvoxamine, initial dose of 50 mg, the dose
can be adjusted once a week, and the maximum dose should under the instruments )
approved by SFDA(China Food and Drug Administration) for OCD treatment which will last
12 weeks. Patients with sleep disorder can combined with Benzodiazepines less than two
consecutive weeks; combination with other psychotropic drugs are forbidden.
Pharmacological combined with psychological treatment: every six or so patients can
establish a closed structured group which is same as the psychological treatment group;
patients start to take medicine at the same time, use of the medicine is same as the
pharmacological treatment group.
3. Follow-up study: After finishing the 12-week treatment, the OCD patients will be into a
6-month follow-up. Patients who are satisfied with pharmacological and/or psychological
treatment will continue the current treatment, while others' follow-up treatment and
specific treatment ways will be decided by researchers through the results of of our
randomized controlled study. Our randomized controlled study results will be divided
into valid and invalid groups. To the invalid psychological or pharmacological treatment
group, patients will have a 12-week combined treatment which means invalid
pharmacological treatment need to combine with psychological treatment and invalid
psychological treatment need to combine with pharmacological treatment. Invalid
pharmacological combined with psychological treatment should adjust the medicine (change
with sertraline/fluvoxamine) and go on the psychological treatment. After the baseline
assessment, OCD patients will have a follow-up evaluation at the 16th, 24th, and 36th
week, while the healthy control will have a follow-up evaluation at the 12th and 36th
week.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |